1. Home
  2. UBX vs XIN Comparison

UBX vs XIN Comparison

Compare UBX & XIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • XIN
  • Stock Information
  • Founded
  • UBX 2009
  • XIN 1997
  • Country
  • UBX United States
  • XIN China
  • Employees
  • UBX N/A
  • XIN N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • XIN Homebuilding
  • Sector
  • UBX Health Care
  • XIN Consumer Discretionary
  • Exchange
  • UBX Nasdaq
  • XIN Nasdaq
  • Market Cap
  • UBX 24.6M
  • XIN 21.7M
  • IPO Year
  • UBX 2018
  • XIN N/A
  • Fundamental
  • Price
  • UBX $1.26
  • XIN $3.70
  • Analyst Decision
  • UBX Strong Buy
  • XIN
  • Analyst Count
  • UBX 3
  • XIN 0
  • Target Price
  • UBX $9.00
  • XIN N/A
  • AVG Volume (30 Days)
  • UBX 70.7K
  • XIN 25.2K
  • Earning Date
  • UBX 11-04-2024
  • XIN 01-01-0001
  • Dividend Yield
  • UBX N/A
  • XIN N/A
  • EPS Growth
  • UBX N/A
  • XIN N/A
  • EPS
  • UBX N/A
  • XIN N/A
  • Revenue
  • UBX N/A
  • XIN $667,143,185.00
  • Revenue This Year
  • UBX N/A
  • XIN N/A
  • Revenue Next Year
  • UBX N/A
  • XIN N/A
  • P/E Ratio
  • UBX N/A
  • XIN $0.42
  • Revenue Growth
  • UBX N/A
  • XIN N/A
  • 52 Week Low
  • UBX $1.11
  • XIN $1.92
  • 52 Week High
  • UBX $2.26
  • XIN $7.05
  • Technical
  • Relative Strength Index (RSI)
  • UBX 47.73
  • XIN 47.06
  • Support Level
  • UBX $1.11
  • XIN $3.80
  • Resistance Level
  • UBX $1.37
  • XIN $4.12
  • Average True Range (ATR)
  • UBX 0.08
  • XIN 0.22
  • MACD
  • UBX 0.00
  • XIN -0.03
  • Stochastic Oscillator
  • UBX 69.49
  • XIN 25.42

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About XIN Xinyuan Real Estate Co Ltd

Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.

Share on Social Networks: